Consistently Records Financial Performance Growth, Prodia Enters Forbes Asia's Best Under a Billion 2021

JAKARTA, 10 September 2021 – PT Prodia Widyahusada Tbk (stock code: PRDA) is one of the Indonesian companies that is included in the Forbes Asia's Best Under a Billion 2021 list. Forbes Asia's Best Under a Billion 2021 is a list containing the 200 best companies in Asia Pacific with income categories above US $ 10 million and below US $ 1 billion or Rp 14 trillion.

President Director of Prodia Dewi Muliaty said, “This achievement is the result of the hard work of all Prodia employees as well as the support and trust of our stakeholders. We continue to strive to record performance growth so that Prodia can always provide added value and optimal returns for our shareholders and stakeholders. We are optimistic that Prodia's business can continue to grow sustainably and contributes to the health ecosystem in Indonesia," said Dewi in response to Forbes Asia's Best Under a Billion 2021 list in Jakarta (10/9).

The criteria set by Forbes Asia in selecting companies in Asia Pacific for the list include growth in earnings per share (EPS) and return on equity (ROE), earnings, and non-financial performance such as corporate governance. Forbes Asia selected the list from 20,000 companies in the Asia Pacific region. The companies, which are included in the list of Forbes Asia's Best Under a Billion 2021, can be categorized as a middle-class company with long-term sustainability performance.

There are 5 (five) Indonesian companies that have successfully entered the Forbes Asia's Best Under a Billion 2021 list, namely PT Prodia Widyahusada Tbk, PT Mitra Keluarga Sejahtera Tbk, PT Medikaloka Hermina Tbk, PT Sido Muncul Tbk, and PT Mark Dynamics Indonesia Tbk.

In the first semester of 2021, Prodia managed to record a net revenue growth of 88.4% to Rp 1.2 trillion and a net profit of Rp 301.02 billion compared to the same period in the previous year. In Semester I 2021, the Company has served more than 8 million health checks consisting of genomic tests, routine tests, COVID-19 tests, and other health checks. Prodia's revenue contribution is dominated by more than 80% by non-COVID tests, namely genomic tests and routine tests. This is in line with Prodia's commitment to promote the concept of health management (personalized medicine) so that one can predict disease risk based on the condition of their respective genes.

Net profit margin and EBITDA margin increased to 24.3% and 35.9%, respectively. The company managed to book a current ratio of 663.1% and a fast ratio of 638.4%. This financial ratio also reflects Prodia's balance sheet which is also getting stronger.

The Company's total assets in the first semester of 2021 recorded an increase to Rp 2.4 trillion compared to the previous year. Total Equity increased to Rp 1.93 trillion compared to 2020 which reached Rp 1.78 trillion. In terms of cash flow, the Company managed to maintain net cash flow from operating activities in a surplus position in the first semester of 2021 to Rp 378.20 billion or an increase of 188.98% compared to the same period in 2020.

Previously, in May 2021 Prodia won the Best Disclosure & Transparency award for the issuer category with a medium market capitalization (Mid Cap) at the 12th IICD Corporate Governance Awards organized by the Indonesian Institute for Corporate Directorship (IICD) at the Financial Hall, Jakarta. In August 2021, Prodia received third place in The Best CSR of the Year for the Public Company-Non Finance category at the Indonesia Corporate Social Responsibility Awards (ICSRA) 2021.

*****

About PT Prodia Widyahusada Tbk

Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. From the very first, Andi Wijaya, along with the other founders have been committed to present the best test results with wholehearted services.

As the market leader, since 2012 Prodia has been the only laboratory and clinic in Indonesia accredited by the College of American Pathologists (CAP). It implies that Prodia' s test results are equal in quality to those obtained from other international laboratories.

On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol 'PRDA'. In that corporate action, Prodia offered 187.5 million shares. Accordingly, the fund raised from the Company' s initial public offering (IPO) was Rp1.22 trillion.

Currently, Prodia has had the service network that incorporates 263 outlets, across 128 cities and 34 provinces in Indonesia, Prodia Health Care (PHC) - a personalized medicine-based wellness clinic - and specialty clinics, including Prodia Children' s Health Centre (PCHC), Prodia Women' s Health Centre (PWHC), and Prodia Senior Health Centre (PSHC).

Prodia has launched Kontak Prodia 1500-830 and the online-based virtual personal assistant Tanya Prodia (TANIA). TANIA can be accessed by anyone, especially Prodia customers directly anytime and anywhere online including via LINE: @prodia.id, Telegram: @prodia.id, Facebook Messenger: @prodia.id and Prodia Website: www.prodia.co.id.

For more information, please visit www.prodia.co.id or contact: